KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBITDA Margin: 2012-2025

Historic EBITDA Margin for Sarepta Therapeutics (SRPT) over the last 11 years, with Jun 2025 value amounting to -73.19%.

  • Sarepta Therapeutics' EBITDA Margin fell 7488.00% to -73.19% in Q2 2025 from the same period last year, while for Jun 2025 it was -13.12%, marking a year-over-year decrease of 1627.00%. This contributed to the annual value of 11.47% for FY2024, which is 5437.00% up from last year.
  • Sarepta Therapeutics' EBITDA Margin amounted to -73.19% in Q2 2025, which was down 398.05% from 24.56% recorded in Q4 2024.
  • Over the past 5 years, Sarepta Therapeutics' EBITDA Margin peaked at 24.56% during Q4 2024, and registered a low of -203.36% during Q1 2023.
  • In the last 3 years, Sarepta Therapeutics' EBITDA Margin had a median value of 1.69% in 2024 and averaged -27.09%.
  • As far as peak fluctuations go, Sarepta Therapeutics' EBITDA Margin tumbled by 15,341bps in 2023, and later soared by 21,170bps in 2024.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' EBITDA Margin stood at -60.55% in 2021, then spiked by 1,887bps to -41.68% in 2022, then surged by 5,357bps to 11.90% in 2023, then surged by 1,266bps to 24.56% in 2024, then tumbled by 7,488bps to -73.19% in 2025.
  • Its EBITDA Margin was -73.19% in Q2 2025, compared to 24.56% in Q4 2024 and 7.90% in Q3 2024.